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AbstrACt
Objectives Outcomes in hepatocellular carcinoma (HCC) 
are determined by both cancer characteristics and liver 
disease severity. This study aims to validate the use of 
inpatient electronic health records to determine liver 
disease severity from treatment and procedure codes.
Design Retrospective observational study.
setting Two National Health Service (NHS) cancer centres 
in England.
Participants 339 patients with a new diagnosis of HCC 
between 2007 and 2016.
Main outcome Using inpatient electronic health 
records, we have developed an optimised algorithm to 
identify cirrhosis and determine liver disease severity 
in a population with HCC. The diagnostic accuracy of 
the algorithm was optimised using clinical records from 
one NHS Trust and it was externally validated using 
anonymised data from another centre.
results The optimised algorithm has a positive predictive 
value (PPV) of 99% for identifying cirrhosis in the 
derivation cohort, with a sensitivity of 86% (95% CI 82% to 
90%) and a specificity of 98% (95% CI 96% to 100%). The 
sensitivity for detecting advanced stage cirrhosis is 80% 
(95% CI 75% to 87%) and specificity is 98% (95% CI 96% 
to 100%), with a PPV of 89%.
Conclusions Our optimised algorithm, based on inpatient 
electronic health records, reliably identifies and stages 
cirrhosis in patients with HCC. This highlights the potential 
of routine health data in population studies to stratify 
patients with HCC according to liver disease severity.
IntrODuCtIOn
Primary liver cancer accounts for 2% of all 
cancers diagnosed in the UK, with approxi-
mately 5700 new cases each year1 and these 
are most commonly hepatocellular carcinoma 
(HCC). It is estimated that 70%–90% of HCC 
occurs in the background of cirrhosis2 3 and 
global outcomes are poor despite a number 
of treatment options.4 Curative treatments 
may be limited by poor liver function due 
to underlying cirrhosis, or late presentation 
of advanced cancer in patients not known 
to have cirrhosis. Therefore, to understand 
outcomes of patients with HCC, it is essen-
tial to consider the presence and severity of 
cirrhosis in all analyses.
Population-based cancer registry data are 
used to describe trends in cancer incidence 
and mortality in a number of cancer sites, as 
well as regional variation in clinical outcomes.5 
In HCC research, registry data have been 
used to describe geographical variation in 
incidence, survival and treatment allocation 
in France.6 In England, the National Cancer 
Registration and Analysis Service (NCRAS) 
dataset contains patient-level information 
about individuals with HCC, but information 
on the presence of cirrhosis is not currently 
included. Also, blood test results are not 
strengths and limitations of this study
 ► First study to use inpatient electronic health records 
to identify and stage cirrhosis severity in a popula-
tion with hepatocellular carcinoma.
 ► The presence of cirrhosis predicted by inpatient 
electronic health records is accurate and advanced 
stage disease identified by the algorithm is asso-
ciated with increased disease severity scores in 
validation.
 ► A potential limitation is a variation in coding practic-
es between centres and over time.
 ► This algorithm may be used in population studies 
to understand outcomes in hepatocellular carcino-
ma, which require an assessment of liver disease 
severity.
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collected, so cirrhosis severity using tools such as the 
Child-Pugh score and the Model for End-Stage Liver 
Disease (MELD) score cannot be calculated.
Previous international studies have outlined methods 
to use electronic health records (EHRs) to identify 
cirrhosis.7–11 In the UK, Ratib et al used a combination 
of inpatient and outpatient records to identify cirrhosis 
and its complications, including oesophageal varices and 
ascites.12 These complications relate to advanced stage 
or ‘decompensated’ cirrhosis and they often result in 
admitted patient care. In England, all inpatient records 
are captured by the Hospital Episode Statistics (HES) 
database, which is linked to the cancer registry data 
within NCRAS.
We present a clinical validation study using EHRs 
from two regional cancer centres in England to assess 
the performance of an algorithm to determine the pres-
ence and severity of cirrhosis using the local inpatient 
HES records, which are subsequently transmitted to the 
national HES dataset. This study aims to demonstrate that 
the use of routinely collected diagnosis and treatment 
codes from inpatient records alone is sufficient to iden-
tify cirrhosis and grade its severity in patients with HCC. 
This will facilitate future studies of outcomes for patients 
with HCC by considering the severity of any underlying 
cirrhosis.
MethODs
All patients diagnosed with HCC between 1 January 2007 
and 31 December 2016 and residents in the secondary 
care catchment area of Leeds Teaching Hospitals NHS 
Trust (LTHT) were identified. The diagnosis of HCC 
was confirmed for all patients in a weekly hepatobiliary 
cancer multidisciplinary team (MDT) meeting and the 
reporting of all cases to the national cancer registry is 
mandatory. HCC was usually diagnosed by radiology, 
using the European Association for the Study of the Liver 
non-invasive criteria,13 and if indicated a targeted biopsy 
was performed. Live minutes are taken at these meetings 
and details collected into the clinical records along with 
a confirmed date of diagnosis. The cohort was identified 
from the data submitted to the central registry. We only 
had access to the inpatient codes from hospital episodes 
which occurred at LTHT. Therefore, only those patients 
registered with a Clinical Commissioning Group local 
to LTHT were included, where we would expect them 
to have received their inpatient cirrhosis care. The local 
HES records were searched to identify inpatient episodes 
containing codes related to cirrhosis within the Interna-
tional Classification of Diseases, 10th revision (ICD-10) 
and Office of Population, Censuses and Surveys’ Clas-
sification, fourth revision (OPCS4), together with the 
corresponding time interval from the HCC diagnosis 
date. These codes are used routinely for reimbursement 
and are submitted to the national HES dataset. An algo-
rithm was developed to characterise patients from these 
codes, and comparison made with the clinical records. 
External validation of the algorithm was undertaken 
using the same search within the local HES records for 
patients diagnosed with HCC between 1 January 2013 
and 31 December 2014 and local to Royal Liverpool and 
Broadgreen University Hospitals NHS Trust (RLBUHT).
Patient and public involvement
Patients and public were not involved in this study.
Identification of cirrhosis
To determine the presence of cirrhosis at HCC diag-
nosis, episodes containing cirrhosis-related codes which 
occurred up to 5 years before the HCC diagnosis date 
were initially included. However, to improve the sensitivity 
of the algorithm by maximising the number of available 
inpatient codes, additional episodes occurring after HCC 
diagnosis were subsequently included. This approach 
assumes that if an inpatient cirrhosis code occurs after the 
HCC diagnosis, the patient is likely to have had cirrhosis 
at the time of HCC diagnosis. The time frame post-HCC 
diagnosis of included episodes was increased incremen-
tally and the performance of the algorithm tested to vali-
date this assumption.
Different definitions of cirrhosis within ICD-10 have 
been used in population studies.14 Some investigators7 8 
used cirrhosis diagnosis codes only, whereas others9 11 also 
included varices codes. Ratib et al15 additionally included 
OPCS4 procedure codes for treatment of varices and 
version 1 of our algorithm is based on this approach. 
Patients are classified as cirrhotic if they had inpatient 
episodes containing the diagnosis and treatment codes 
for cirrhosis or varices outlined in table 1. In version 2, 
a broader definition of cirrhosis proposed by Leon and 
Table 1 Treatment and procedure codes included in the 
algorithm to determine cirrhosis status and cirrhosis severity
Codes
Cirrhosis diagnoses (ICD-10): 
  Cirrhosis K70.3, K71.7, K72.1, K74.4, 
K74.5, K74.6, K76.6, K72.1, 
K72.9
  Alcoholic hepatic failure K70.4
  Alcoholic liver disease K70.9
  Ascites R18.X
  Varices I85.9, I86.4, I98.2
  Bleeding varices I85.0, I98.3
Cirrhosis treatments (OPCS4):
  Treatment of ascites T46.1, T46.2, J06.1, J06.2
  Treatment of varices G10.4, G10.8, G10.9, G14.4, 
G17.4, G43.4, G43.7, J06.1, 
J06.2
Gastrointestinal haemorrhage 
(ICD-10):
  Gastrointestinal 
haemorrhage
K92.0, K92.1, K92.2
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McCambridge16 was used, including codes for ‘alcoholic 
liver disease’ (ALD, K70.9) and ‘alcoholic hepatic failure’ 
(AHF, K70.4). To assess the accuracy of including ascites 
as a cirrhosis-defining condition in HCC, codes for ascites 
and paracentesis were included in version 3 of the algo-
rithm. Previously, some investigators9 15 excluded ascites 
in their definitions because this may be due to malig-
nancy in the absence of cirrhosis in a general population. 
In version 4, only ascites codes occurring before the HCC 
diagnosis date were included.
The clinical records were reviewed between April and 
August 2018 and data abstracted by three clinical inves-
tigators (RJD, VB and JS), each experienced hepatology 
fellows working in this field for at least 2 years. A stan-
dard abstraction form was used and discrepancies were 
resolved by consensus view. Cirrhosis at the time of HCC 
diagnosis was identified based on explicit mention of 
cirrhosis in the clinical record or MDT minutes, evidence 
of portal hypertension on radiological imaging or endos-
copy reports, explicit mention of cirrhosis on liver biopsy 
or a consistent result on transient elastography. This was 
used as the gold standard for testing different versions of 
the algorithm to classify cirrhosis status. For comparison, 
published algorithms7–9 15 were also tested in the LTHT 
cohort of patients with HCC.
Classification of cirrhosis severity
Cirrhosis severity was classified using the Baveno IV 
consensus.17 Compensated cirrhosis is defined by Baveno 
stage 1 (no ascites or varices) and stage 2 (non-bleeding 
varices). Decompensated cirrhosis is defined by Baveno 
stage 3 (ascites, with or without varices) and stage 4 
(bleeding varices, with or without ascites). In this model 
of the natural history of cirrhosis,3 patients progress to 
a higher Baveno stage over time, but do not return to a 
lower stage. For each hospital episode, the Baveno stage 
and compensation status were calculated using the diag-
nosis and treatment codes for ascites and varices in table 1. 
Three definitions of bleeding varices were tested; version 
A (based on Goldberg et al10) contains ICD-10 codes 
for variceal bleeding, version B (based on Ratib et al12) 
also includes OPCS4 codes for treatment of varices, and 
version C limits the inclusion of these treatment codes to 
those occurring in a hospital episode with a concurrent 
ICD-10 code for gastrointestinal haemorrhage (K92.0, 
K92.1 and K92.2). This is to distinguish between bleeding 
varices and the prophylactic treatment of non-bleeding 
varices.
Cirrhosis severity at the time of HCC diagnosis was deter-
mined by the highest Baveno stage recorded in hospital 
episodes occurring in the 5 years before HCC diagnosis. 
In order to increase the accuracy of this assessment, addi-
tional episodes occurring after the HCC diagnosis date 
were also included. The time frame post-HCC diagnosis 
of included episodes was increased incrementally up to 
4 months. The clinical records were reviewed to deter-
mine the true Baveno stage at the time of HCC diagnosis, 
along with routine blood tests for calculation of Child 
Pugh and MELD scores. Baveno stage 2 was identified by 
non-bleeding varices explicitly mentioned in the clinical 
records or endoscopy reports, but excluded a report of 
portal hypertensive gastropathy. Baveno stage 3 was iden-
tified by explicit mention of ascites in the clinical record, 
requiring diuretic therapy or paracentesis, but a small 
volume of ascites only visible on cross-sectional imaging 
was excluded. Baveno stage 4 was identified by explicit 
mention of variceal haemorrhage in the clinical record 
or endoscopy reports. Clinical evidence of decompensa-
tion was identified by the presence of bleeding varices or 
ascites, as per the Baveno IV classification.
statistical analysis
Data management and statistical analysis were performed 
using Stata V.15.1 (StataCorp). The diagnostic accuracy of 
the algorithm to identify cirrhosis status and decompen-
sation status involved comparison of sensitivity and spec-
ificity derived from 2×2 contingency tables.18 For Baveno 
stage, agreement between the algorithm and the clinical 
records were assessed using the kappa statistic. This is 
used to assess observer agreement for categorical vari-
ables and allows for agreement occurring by chance.19 20
results
study population
During the study period, 289 patients (median age 69, 
79% male) with a new diagnosis of HCC were included 
(table 2) and 249 (86.2%) of these had an inpatient 
record. Review of the clinical record identified 191 
(66%) of these as cirrhotic at HCC diagnosis, 50 (26%) 
of whom had evidence of previous decompensation. The 
median age of the cirrhotic group was 67 compared with 
73 in the non-cirrhotic group (p<0.001). An additional 
15 patients had histological evidence of advanced fibrosis 
but cirrhosis was not mentioned explicitly in the clinical 
records. Among the patients who did not have an inpa-
tient record, 12 had cirrhosis according to outpatient case 
note review. In the external validation cohort at RLBUHT, 
50 patients meeting the inclusion criteria were assessed 
(median age 71, 82% male), 31 (62%) of whom were 
cirrhotic and 11 (35%) with previous decompensation.
Identification of cirrhosis
Limiting the inclusion of episodes to those occurring 
before the HCC diagnosis results in a sensitivity of less 
than 50% for cirrhosis detection (table 3). When addi-
tional episodes are included up until 3 years after the 
HCC diagnosis, the sensitivity increases to greater than 
80% for all versions of the algorithm, without significant 
loss of specificity.
The sensitivity of algorithm 1 is increased by including 
ALD and AHF (version 2), and further increased by 
including ascites (version 3). However, the inclusion 
of ascites also reduces the specificity. This is overcome 
by limiting the inclusion of ascites to episodes that 
occurred before the HCC diagnosis (version 4). Using 
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this optimised algorithm and including records up to 
3 years post-HCC diagnosis, the sensitivity is 86% (95% 
CI 82% to 90%) and the specificity is 98% (95% CI 96% 
to 100%), with a positive predictive value (PPV) of 99% 
and negative predictive value (NPV) of 79% (95% CI 74% 
to 83%) (online supplementary table 1). For external 
validation, when V.4 of the algorithm was applied to the 
RLBUHT cohort with 3 years of follow-up, the sensitivity 
Table 2 Baseline characteristics of the LTHT cohort
Characteristic 
Total
N (%)
No cirrhosis
N (%)
Cirrhosis
N (%)
P value289 98 (33.9%) 191 (66.1%)
Age group 
  <50 22 (7.6) 10 (10.2) 12 (6.3) 0.26
  50–59 49 (17.0) 10 (10.2) 39 (20.4) 0.04
  60–69 81 (28.0) 18 (18.4) 63 (33.0) 0.03
  70–79 92 (31.8) 31 (31.6) 61 (31.9) 0.95
  80+ 45 (15.6) 29 (29.6) 16 (8.4) <0.001
Sex 
  Male 228 (78.0) 76 (77.6) 152 (79.6) 0.83
  Female 61 (21.1) 22 (22.4) 39 (20.4) 0.73
Ethnicity 
  White 252 (87.1) 87 (88.8) 165 (86.4) 0.86
  Black 12 (4.2) 5 (5.1) 7 (3.7) 0.58
  South Asian 12 (4.2) 2 (2.0) 10 (5.2) 0.21
  Chinese 4 (1.4) 0 4 (2.1) 0.15
  Other Ethnic group 4 (1.4) 1 (1.0) 3 (1.6) 0.70
  Not stated 5 (1.7) 3 (3.1) 2 (1.0) 0.22
Aetiology 
  HCV 44 (15.2) 4 (4.1) 40 (20.9) <0.001
  HBV 17 (5.9) 5 (5.1) 12 (6.3) 0.69
  PBC 7 (2.4) 0 7 (3.7) 0.06
  AIH 3 (1.0) 0 3 (1.6) 0.21
  Haemochromatosis 19 (6.6) 5 (5.1) 14 (7.3) 0.48
  Alcohol 68 (23.5) 4 (4.1) 64 (33.5) <0.001
  NAFLD 43 (14.9) 13 (13.3) 30 (15.7) 0.60
  Other/unknown 88 (30.4) 67 (68.4) 21 (11.0) <0.001
MELD 
  <10 90 (47.1)
  10–14 73 (38.2)
  15–19 21 (11.0)
  20+ 7 (3.7)
Child-Pugh 
  A 131 (68.6)
  B 44 (23.0)
  C 16 (8.4)
Previous decompensation 
  Ascites 37 (19.3)
  Variceal bleed 13 (6.8)
 AIH, autoimmune hepatitis; HBV, hepatitis B virus; HCV, hepatitis C virus; LTHT, Leeds Teaching Hospitals NHS Trust; MELD, Model for End-
Stage Liver Disease; NAFLD, non-alcoholic fatty liver disease; PBC, primary biliary cirrhosis. 
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was 79% and specificity was 100%. Additionally, version 4 
of the algorithm outperformed published algorithms for 
cirrhosis detection when they were applied to the LTHT 
cohort of patients with HCC (table 4).
Classification of cirrhosis severity
Table 5 shows the performance of the three versions 
of the algorithm for determining cirrhosis severity 
according to Baveno stage. Compared with version A, 
there is slightly less agreement between the calculated 
Baveno stage and the clinical record in version B, where 
Baveno stage 4 is defined by procedure codes for varices. 
Similarly, the sensitivity for detecting decompensation 
(defined by Baveno stages 3 and 4) is increased in version 
B, but with reduced specificity (online supplementary 
table 2). Agreement between the algorithm and the 
clinical record is optimised in version C, when bleeding 
varices are defined by a concurrent gastrointestinal haem-
orrhage code. Agreement was further improved when 
episodes occurring within 60 days of the registered HCC 
diagnosis were included. The performance characteris-
tics of the component codes are summarised in online 
supplementary tables 3 and 4; the sensitivity for detecting 
bleeding varices is increased in algorithm B, but the PPV 
and overall agreement with the Baveno stage is reduced 
due to the misclassification of non-bleeding varices. The 
sensitivity for detecting ascites is increased when both 
diagnosis and paracentesis procedure codes are included.
Using version C with a 60-day interval in the LTHT 
cohort, agreement between the clinical record and calcu-
lated Baveno stage was 84%, with a kappa coefficient of 
0.74 (95% CI 71% to 77%). The sensitivity for detecting 
prior decompensation is 80% (95% CI 75% to 85%) and 
specificity is 98% (95% CI 96% to 100%), with a PPV 
of 89% (95% CI 85% to 93%) and NPV of 96% (95% 
CI 94% to 98%). When this version was applied to the 
RLBUHT cohort for external validation, the agreement 
of Baveno stage with the clinical record was 81% (kappa 
0.70). The sensitivity for detecting decompensation was 
73% and specificity was 90%.
Finally, among the 167 LTHT patients identified as 
cirrhotic by the algorithm, 45 (27%) were coded with 
prior decompensation. At the time of HCC diagnosis, 
Child-Pugh class and MELD scores were each higher 
in those individuals identified with decompensation 
(figure 1).
DIsCussIOn
Main findings
This study demonstrates the reliability of an algorithm 
using inpatient HES records to identify and stage 
cirrhosis in patients with HCC. This is the first such 
algorithm validated in a UK population that uses only 
inpatient codes. Using inpatient codes from the whole 
Table 4 Performance of different published algorithms for cirrhosis detection in the LTHT cohort of patients with HCC
Algorithm
Sensitivity 
(%)
95% CI Specificity 
(%)
95% CI
PPV (%)
95% CI
Lower Upper Lower Upper Lower Upper
Kramer et al7 72 67 77 100 100 100 100 100 100
Jepsen et al8 71 66 76 100 100 100 100 100 100
Nehra et al9 80 76 85 98 96 100 99 97 100
Ratib et al15 80 76 85 98 96 100 99 97 100
Algorithm 4 86 82 90 98 96 100 99 97 100
HCC, hepatocellular carcinoma; LTHT, Leeds Teaching Hospitals NHS Trust; PPV, positive predictive value.
Table 5 Performance of different versions of the Baveno stage algorithm
Time after HCC 
diagnosis/days
Algorithm A
Variceal bleeding codes
Algorithm B
Variceal bleeding codes or 
treatment codes
Algorithm C
Variceal bleeding codes or 
treatment codes+UGIB
Correct Baveno 
stage (%) Κ-statistic
Correct Baveno 
stage (%) Κ-statistic
Correct Baveno 
stage (%) Κ-statistic
0 80 0.67 80 0.67 81 0.70
30 82 0.70 81 0.70 83 0.73
60 83 0.71 82 0.71 84 0.74
90 81 0.69 80 0.69 82 0.71
120 81 0.69 80 0.69 82 0.71
HCC, hepatocellular carcinoma; UGIB, Upper gastrointestinal bleeding.
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follow-up period improves the sensitivity of the algorithm 
in cirrhosis identification, without loss of specificity. This 
validates the assumption that if a patient had an inpa-
tient cirrhosis code during follow-up, they had cirrhosis 
at the time of HCC diagnosis. Using a broad definition of 
cirrhosis (versions 2–4) improves sensitivity and accounts 
for variations in coding practice in which ALD and AHF 
are coded synonymously with cirrhosis. Excluding ascites 
after HCC diagnosis (version 4) improves the specificity; 
ascites in liver disease without HCC is most likely to be 
due to cirrhosis, whereas it may be malignant ascites in 
the context of HCC. Algorithm 4 is an improvement 
over published algorithms for cirrhosis detection when 
they are applied to our cohort of patients with HCC. 
Algorithm C (for assessing cirrhosis severity) also outper-
formed published versions in this population. Inclusion 
of a concurrent gastrointestinal haemorrhage code along-
side variceal procedures distinguishes between treatment 
of bleeding varices and treatment of non-bleeding varices 
for primary prevention.
strengths and limitations
The strengths of this study are the systematic develop-
ment of an algorithm which uses routinely available 
inpatient episode codes, and its applicability to large 
population studies in HCC. These patients often require 
hospital admission to manage complications in advanced 
cirrhosis and to receive HCC therapies, or day case proce-
dures such as paracentesis and endoscopy which are also 
coded in the HES dataset. The high-performance char-
acteristics (particularly the PPVs) derived from inpatient 
codes here are in part a consequence of the high pretest 
probability of cirrhosis in patients with HCC. This obser-
vation is supported by the improved PPVs seen in existing 
algorithms in our cohort. In summary, this suggests that 
inpatient episodes are sufficient for high-quality analyses 
of the impact of cirrhosis and its severity on the outcomes 
of patients with HCC.
This study benefits from robust case note evalua-
tion, using both a development and external valida-
tion cohort. In the UK, previous validation of inpatient 
coding was achieved using free-text analysis of primary 
care and death certification data,12 and the orig-
inal case note validation of the cirrhosis algorithm 
included only 36 patients.21 The algorithm benefits 
from exploiting the ‘anchor point’ of the HCC diag-
nosis date, so that inpatient codes can be associated 
with a time interval. This has led to optimised cirrhosis 
detection and severity classification. The algorithm 
for cirrhosis detection was optimised using 3 years of 
follow-up after HCC diagnosis, but the high sensitivity 
and specificity using 1-year of follow-up may be suffi-
cient in some settings.
The limitations include its location in specialist 
cancer centres, which may not reflect coding prac-
tices throughout the UK and these may change over 
time. However, portal hypertensive complications 
are common and often result in inpatient care and, 
since these are high-cost procedures, we anticipate 
them to be reliably coded. The analysis was limited to 
patients local to the two centres, in order to capture 
cirrhosis-related episodes. Additional episodes may 
have been missed if patients were admitted else-
where, but these would be captured by the algorithm 
when extended to a national dataset. The majority 
of patients had an inpatient record, suggesting high 
rates of hospital admission in patients with cirrhosis 
and those undergoing HCC treatment. The limitations 
of using inpatient codes alone are common to other 
studies which have utilised the linked inpatient HES 
dataset to produce impactful analyses.22 23
The proportion of patients with cirrhosis identified 
from their clinical records was 66% and this is lower than 
previous reports.2 3 By limiting to inpatient codes, the 
algorithm missed 12/191 (6.3%) patients with cirrhosis 
and those with histological evidence of advanced fibrosis 
were classified as non-cirrhotic. Many patients were diag-
nosed with HCC in the absence of known liver disease; 
68.4% of those without cirrhosis had no known under-
lying liver disease aetiology (table 2). If patients had 
advanced cancer at presentation, their clinical record 
may not have explicitly stated the presence of cirrhosis. 
Additionally, they may have not been investigated further 
Figure 1 Box-and-whisker plots showing the distribution of MELD scores (A) and pie graphs showing the distribution of Child-
Pugh class (B) within compensated and decompensated cirrhosis groups determined by the algorithm. MELD, Model for End-
Stage Liver Disease.
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to establish a diagnosis of cirrhosis if not clinically appro-
priate. It is also notable that there was a high proportion 
of patients aged over 80 years who were not identified to 
have cirrhosis. Finally, the definition of decompensation 
using the Baveno IV classification is limited because it 
does not capture hepatic encephalopathy (HE), which 
may occur without variceal bleeding or ascites. HE can 
be coded in ICD-10 code as ‘hepatic coma’, but we found 
that this was used uncommonly in our cohort and so 
we did not broaden our definition of decompensation 
beyond that used by Ratib et al.12
Implications
This algorithm can be applied to population cancer regis-
tries in the UK, enabling the identification and staging 
of cirrhosis in patients with HCC. This is essential for 
assessing clinical outcomes in population-based studies of 
individuals with HCC both in the UK and elsewhere. It is 
anticipated that this will lead to a better understanding of 
outcomes in HCC, including progression of underlying 
liver disease severity as well as overall survival. The algo-
rithm may also be used in other population-based appli-
cations, which require the identification of cirrhosis and 
an assessment of severity.
In this study, we demonstrated the use of inpatient HES 
records to determine the cirrhosis severity at the time of 
HCC diagnosis. The algorithm may be adapted to clas-
sify the Baveno stage at different time intervals following 
HCC diagnosis or date of treatment, so that subsequent 
cirrhosis decompensation events can be identified over 
time. This approach is likely to have value in other health 
systems and we anticipate that the algorithm described 
will be evaluated by other investigators in outcomes-ori-
ented research in cirrhosis and HCC.
COnClusIOn
This study demonstrates the reliability of an algorithm 
based on inpatient EHRs to stratify patients with HCC 
according to the presence and severity of cirrhosis. It may 
be used in routine health data in order to assess outcomes 
in HCC in population studies.
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